Physician profile
Atul Kothari
NPI 1265749626
$762.99
in general payments reported to CMS, 2019-2025
18 companies · $220 in 2025
The $220 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.00 · 2022: $39.99 · 2023: $121 · 2024: $283 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $624.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $160.89 | 2021-2024 | Cresemba |
| Abbvie INC. | $84.99 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $60.19 | 2024 | Recarbrio, Dificid, Zerbaxa |
| Mallinckrodt Hospital Products INC. | $59.31 | 2023-2025 | Acthar |
| United Therapeutics Corporation | $53.04 | 2023-2025 | Tyvaso, Tyvaso |
| Melinta Therapeutics, LLC | $49.67 | 2024-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Ani Pharmaceuticals, INC. | $46.58 | 2025 | Purified Cortrophin Gel |
| Gilead Sciences, INC. | $39.75 | 2024 | |
| Electromed, INC. | $30.16 | 2023-2024 | Smartvest |
| La Jolla Pharmaceutical Company | $24.88 | 2024 | Xacduro |
| Paratek Pharmaceuticals, INC. | $22.84 | 2025 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $22.71 | 2025 | Glassia |
| Theratechnologies INC. | $21.58 | 2024 | Trogarzo, Egrifta |
| Pfizer INC. | $20.31 | 2025 | |
| Baxter Healthcare | $19.45 | 2024 | Hillrom - Vest System Model 105 Home Care |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $17.98 | 2024 | |
| Viiv Healthcare Company | $15.40 | 2024 | Dovato |
| Nevro Corp. | $13.26 | 2023 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atul Kothari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.